 Shares of San Francisco-based Lyell Immunopharma Inc. , a clinical-stage biotech that is developing T cell therapies for solid tumors, stumbled in their trading debut Thursday, falling 2.2 at last check. The company sold 25 million shares priced at 17 each, the midpoint of its 16- to-18 price range to raise 425 million. 